Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands.
Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.'
Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.'
SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors.
ENDS
About Anocca
Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments.
Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca.
About the VIDAR-1 clinical programme
VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product.
More information about the clinical trial can be found at the EU's clinical trials website.
About KRAS and PDAC
Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2).
References
1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166
2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Introducing Cambridge Forum 2025: Tech for Good
CAMBRIDGE, England--(BUSINESS WIRE)-- Cambridge Forum 2025, themed 'Tech for Good', is set to bring together global technology leaders, development innovators, policymakers, entrepreneurs, and academics in Cambridge this September. This two-day event discusses technology as a force for inclusive empowerment and positive social impact. Our Vision: From Underserved to Unstoppable At Cambridge Forum, we believe that technology can transform lives—especially in underserved communities. Rooted in Cambridge's academic and innovation ecosystem, we will foster collaboration across technology, development, academia, policy, and the private sector to bring solutions to the world's pressing challenges. Taking place in the historic city of Cambridge—a global hub for intellectual discovery—the Forum aims to be a permanent platform for inclusive collaboration across disciplines, sectors, and geographies. 'We believe the world's toughest challenges can't be solved in silos. Cambridge Forum offers a shared space to design, build, and scale innovation for good,' said Dr. Ehab Shanti, Founding Director of Cambridge Forum. 'AI undoubtedly presents enormous derivative challenges, but it also creates significant opportunities. Cambridge Forum will explore both,' he added. Cambridge Forum 2025 will feature a high-impact line-up of world-class speakers and changemakers, including: Marty Neumeier – Highly influential American author, designer, and business advisor focused on the intersection of design, branding, and innovation will deliver a session on 'Goodness as Corporate DNA'. Jaideep Prabhu – Co-author of Jugaad Innovation: Think Frugal, Be Flexible, will deliver a session on" Frugal Innovation: Leveraging Digital Public Infrastructure for Inclusive Artificial Intelligence'. Dr. Gareth Corbett, Chief Medical Officer, Onion AI will discuss, 'Tech for Good, The Case of AI and Health'. Henning Grosse Ruse Khan - Professor of Law at the University of Cambridge will discuss, 'Can We Regulate AI to Prevent Harm?'. Why It Matters In a time of global complexity and rapid technological advancement, we aim to ensure no one is left behind. By fostering cross-sector collaboration and offering practical tools, Cambridge Forum helps turn big ideas into real-world solutions to address the world's most pressing issues. About Cambridge Forum Cambridge Forum is a training and knowledge-sharing event that provides participants with a unique opportunity to learn. Through practical training and real-world applications, we will discuss how to harness advanced technology in AI and Insurtech to address the world's most pressing challenges and serve underserved communities.
Yahoo
2 hours ago
- Yahoo
Best's Market Segment Report: Swiss Re's Adoption of IFRS 17 Shuffles the Top Tier in AM Best's "World's 50 Largest Reinsurers" Rankings
OLDWICK, N.J., August 18, 2025--(BUSINESS WIRE)--Swiss Re's adoption of IFRS 17 has resulted in some shifts atop AM Best's rankings of the world's largest reinsurers, which differ based on accounting standards. The Best's Market Segment Report, "World's 50 Largest Reinsurers," is a highly recognized part of AM Best's overall look at the global reinsurance industry ahead of the Rendez-Vous de Septembre in Monte Carlo. Other reports, including AM Best's in-depth looks at the insurance-linked securities, Lloyd's, life/annuity, health and regional reinsurance segments, will be available during August and September. Swiss Re had previously reported under GAAP standards, but with this change now moves from first among the non-IFRS 17 reporters last year to first among IFRS 17 reporters. This bumped Munich Re from the top spot among IFRS 17 reporters to second, followed by Hannover Rück SE placing third. Swiss Re reported USD 40.5 billion of gross premiums written at year-end 2023 and USD 36.2 billion of reinsurance revenue at year-end 2024. In terms of loss performance, Munich Re led with a non-life reinsurance combined ratio of 77.3, compared to 85.2 for the year prior. Among the top five non-IFRS 17 players, the most significant change is Berkshire Hathaway moving into the top position, with USD 26.9 million of gross premiums written, followed by Lloyd's with USD 23.5 billion. The top 5 IFRS 17 players had a solid performance in 2024, reporting a weighted average combined ratio of 84.9. Last year's edition of the World's 50 Largest Reinsurers report introduced two separate rankings based on gross premiums written for non-IFRS 17 reporting reinsurers and reinsurance revenue for IFRS 17 reporters. This now marks the second full year of financial information being reported under IFRS-17, which has provided AM Best with additional insights into the year-over-year performance of reinsurers ranked in the report. The report notes that global reinsurers' results for 2025 will depend upon activity during the Atlantic hurricane season. "The California wildfires in January heavily impacted results for the first quarter, with many reinsurers who had California exposure reporting their worst quarterly underwriting experience in recent years and the impact of the wildfires eroding substantial portions of budgeted catastrophe loads for the year," said Chris Pennings, financial analyst, AM Best. "As 2025 plays out, the market has witnessed pockets of rate softening among non-loss affected accounts, though rates modestly improved or maintained on loss affected accounts." To access the full copy of this market segment report, please visit For global reinsurance reports ahead of Rendez-Vous de Septembre, as well as video coverage of the event, please visit AM Best's Reinsurance Information center. Lastly, AM Best will host its annual reinsurance market briefing at Rendez-Vous de Septembre on Sept. 7, 2025, at 10:15 a.m. (CEST) in Monte Carlo. For more information, please visit the event website. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Christopher Pennings, CPCU Financial Analyst +1 908 882 2237 Dan Hofmeister, CFA, FRM, CAIA, CPCU Associate Director +1 908 882 1893 Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 Al Slavin Senior Public Relations Specialist +1 908 882 2318
Business Wire
2 hours ago
- Business Wire
Best's Market Segment Report: Swiss Re's Adoption of IFRS 17 Shuffles the Top Tier in AM Best's 'World's 50 Largest Reinsurers' Rankings
BUSINESS WIRE)--Swiss Re's adoption of IFRS 17 has resulted in some shifts atop AM Best 's rankings of the world's largest reinsurers, which differ based on accounting standards. The Best's Market Segment Report, 'World's 50 Largest Reinsurers,' is a highly recognized part of AM Best's overall look at the global reinsurance industry ahead of the Rendez-Vous de Septembre in Monte Carlo. Other reports, including AM Best's in-depth looks at the insurance-linked securities, Lloyd's, life/annuity, health and regional reinsurance segments, will be available during August and September. Swiss Re had previously reported under GAAP standards, but with this change now moves from first among the non-IFRS 17 reporters last year to first among IFRS 17 reporters. This bumped Munich Re from the top spot among IFRS 17 reporters to second, followed by Hannover Rück SE placing third. Swiss Re reported USD 40.5 billion of gross premiums written at year-end 2023 and USD 36.2 billion of reinsurance revenue at year-end 2024. In terms of loss performance, Munich Re led with a non-life reinsurance combined ratio of 77.3, compared to 85.2 for the year prior. Among the top five non-IFRS 17 players, the most significant change is Berkshire Hathaway moving into the top position, with USD 26.9 million of gross premiums written, followed by Lloyd's with USD 23.5 billion. The top 5 IFRS 17 players had a solid performance in 2024, reporting a weighted average combined ratio of 84.9. Last year's edition of the World's 50 Largest Reinsurers report introduced two separate rankings based on gross premiums written for non-IFRS 17 reporting reinsurers and reinsurance revenue for IFRS 17 reporters. This now marks the second full year of financial information being reported under IFRS-17, which has provided AM Best with additional insights into the year-over-year performance of reinsurers ranked in the report. The report notes that global reinsurers' results for 2025 will depend upon activity during the Atlantic hurricane season. 'The California wildfires in January heavily impacted results for the first quarter, with many reinsurers who had California exposure reporting their worst quarterly underwriting experience in recent years and the impact of the wildfires eroding substantial portions of budgeted catastrophe loads for the year,' said Chris Pennings, financial analyst, AM Best. 'As 2025 plays out, the market has witnessed pockets of rate softening among non-loss affected accounts, though rates modestly improved or maintained on loss affected accounts.' To access the full copy of this market segment report, please visit For global reinsurance reports ahead of Rendez-Vous de Septembre, as well as video coverage of the event, please visit AM Best's Reinsurance Information center. Lastly, AM Best will host its annual reinsurance market briefing at Rendez-Vous de Septembre on Sept. 7, 2025, at 10:15 a.m. (CEST) in Monte Carlo. For more information, please visit the event website.
